Sales of branded anti-obesity drugs (AOB) could hit $44 billion in 2030 vs $2.5 billion in 2022, with just under 70% stemming from the US. The predictions come from analysts at Bloomberg Intelligence (BI), who believe securing broad reimbursement and supply are key, with a possible upside from further innovations including combination products. Michael Shah, […]